Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

2018 Masitinib Drug Analysis: An Oral Tyrosine Kinase Inhibitor Being Developed by AB Science -

Research and Markets
Posted on: 15 Feb 18

The "Drug Analysis: Masitinib" drug pipelines has been added to's offering.

Masitinib (AB Science) is an oral tyrosine kinase inhibitor being developed by AB Science. It targets a number of receptor tyrosine kinases including c-Kit, fibroblast growth factor receptor 3, platelet-derived growth factor receptor alpha/beta, lymphocyte-specific protein tyrosine kinase (Lck), Lck/Yes-related novel protein tyrosine kinase, and focal adhesion kinase.

This makes the drug effective at controlling the survival, differentiation, and degranulation of mast cells, which are involved in oncogenic processes such as angiogenesis, tissue remodeling, and immunomodulation.

Product Profiles

  • masitinib: Prostate cancer
  • masitinib: Colorectal cancer (CRC)
  • masitinib: Asthma
  • masitinib: Pancreatic cancer

For more information about this drug pipelines report visit

View source version on

Business Wire

Last updated on: 15/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.